GSK 3003891A

Drug Profile

GSK 3003891A

Alternative Names: GSK-300389; GSK-3003891A; GSK-3003892A; GSK-3003893A; GSK-3003895A; GSK-3003896A; GSK-3003898A; GSK-3003899A; Pre F protein - GlaxoSmithKline; PreF - GlaxoSmithKline

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Respiratory syncytial virus vaccines; Viral fusion proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 01 Nov 2016 GlaxoSmithKline initiates a phase II trial in Respiratory syncytial virus infections (Prevention) in Germany (IM) (NCT02956837, EudraCT2016-001135-12)
  • 05 Oct 2016 Phase-II clinical trials in Respiratory syncytial virus infections (Prevention) in Estonia (IM) (EudraCT2016-001135-12)
  • 28 Jun 2016 GlaxoSmithKline completes phase-II clinical trials in Respiratory syncytial virus infections (Prevention) in Belgium (IM) (EudraCT2015-005742-58)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top